Pennytobuck.com Stock Update On Orex, Ulta And Crwe For Thursday September 9th,

Crown Equity Holdings Inc

Crown Equity Holdings Inc. (OTCBB:CRWE)

CRWE release news that its sales this year have already surpassed $1,000,000.

This compares to $232,510 for the three quarters ending September 30, 2009 and $ 659,907 total sales for the year 2009.

Kenneth Bosket, President and CEO of Crown Equity Holdings Inc. commented "Based on our sales to date, we had more than 4 times the sales for the same period last year and are 34% ahead of last year's total sales."

Mr. Bosket also stated "Our growth in sales along with our investments in infrastructure and people give the company a basis for supporting future growth of the magnitude we have seen so far this year."

CRWE has also moved to a dedicated in-house advertising server, allowing for faster response and a wider variety of ad space offerings to those interested in advertising on their numerous internet and affiliate internet properties.

CRWE is currently in the process of expanding its in-house IT infrastructure. Although their current web page load time is better than 75% of other internet websites, when completed, the modifications will raise this load time to better then 90% of other internet websites while increasing website visitor capacity by 400%.

CRWE has expanded its internet footprint internationally to include the following 19 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Korea, Mexico, New Zealand, Singapore, Spain, Taiwan and the UK.

Orexigen Therapeutics Inc., OREX

Orexigen Therapeutics Inc., (NasdaqGM:OREX) took the spotlight early Thursday as shares of the biotech group soared as they signed a North American partnership for its experimental obesity drug Contrave with Takeda Pharmaceutical Co. for $50 million and the potential for later payments that could exceed $1 billion.

Under the terms of the deal, Takeda will market the product in the U.S., Mexico and Canada upon approval. Orexigen will receive $50 million up front and is eligible for more than $1 billion in various milestone payments. Orexigen will also receive tiered double-digit royalties on sales.

Orexigen expects to receive a decision from the U.S. Food and Drug Administration on Contrave by Jan. 31, 2011.

Contrave is one of three new diet drugs up for FDA approval.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The companys Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.

Keep OREX on your watch list. This new obesity drug once approved, can help OREX stock take off!!

Please Visit: www.orexigen.com for more information!

Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA), recently announced on September 2nd, 2010 financial results for the thirteen week period (Second Quarter) and twenty-six week period (First Six Months) ended July 31, 2010, which compare to the same periods ended August 1, 2009.

For the Second Quarter:

Net sales increased 17.6% to $321.8 million from $273.5 million in the second quarter of fiscal 2009;

Comparable store sales (sales for stores open at least 14 months) increased 10.8% compared to a decrease of 1.7% in the second quarter of fiscal 2009;

Gross profit increased 350 basis points to 32.3% from 28.8% in the second quarter fiscal 2009;

Selling, general and administrative (SG&A) expense as a percentage of net sales decreased 40 basis points, excluding the impact of the non-recurring compensation charge, compared to the second quarter in fiscal 2009; including the impact of the non-recurring compensation charge, SG&A as a percentage of net sales increased 50 basis points;

Operating income increased 117.4% to $22.3 million, or 6.9% of net sales, compared to $10.2 million, or 3.7% of net sales, in the second quarter of fiscal 2009;

Net income increased 127.2% to $13.1 million compared to $5.8 million in the second quarter of fiscal 2009;

Income per diluted share more than doubled to $0.22, including $0.03 per diluted share related to the non-recurring compensation charge. Income per diluted share was $0.25, excluding the non-recurring compensation charge. This compares to $0.10 in the second quarter of fiscal 2009.

Conference Call Information

A conference call to discuss second quarter results is scheduled for today, September 2, 2010, at 5:00 p.m. Eastern Time. Investors and analysts interested in participating in the call are invited to dial (877) 407-0784 approximately ten minutes prior to the start of the call. The conference call will also be web-cast live at http://ir.ulta.com and remain available for 90 days. A replay of this call will be available until 11:59 p.m. (ET) on September 9, 2010 and can be accessed by dialing (877) 660-6853 and entering account number 3055 and conference ID number 355010.

ULTA is the largest beauty retailer that provides one-stop shopping for prestige, mass and salon products and salon services in the United States. Ulta provides affordable indulgence to its customers by combining the product breadth, value and convenience of a beauty superstore with the distinctive environment and experience of a specialty retailer. Ulta offers a unique combination of over 21,000 prestige and mass beauty products across the categories of cosmetics, fragrance, haircare, skincare, bath and body products and salon styling tools, as well as salon haircare products. Ulta also offers a full-service salon in all of its stores. The Company currently operates 356 retail stores across 38 states and also distributes its products through the Companys website: www.ulta.com.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

by: Bill Pennyman

POST COMMENT

It's All There To See And Do What Are The Best Mobility Scooters and Scooter Ramps? Cbis, Wpnv And Yrcw Stock Report From Pennytobuck.com Choose The Best Canadian Discount Stock Brokerage Moisture Control And The Building Envelope In Winnipeg, Mb Dtsl, Eqlb And Mrvl Stock Update From Pennytobuck.com Brcm, Rfmd And Nuec Stock Updates From Pennytobuck.com Pancreatitis Los Angeles-Alcoholism and pancreatitis Ways To Organize A Cookie Dough Fundraiser Discipline And Toddlers Understanding The 3 Kinds Of Discipline. Custom Signs - The Good, The Bad, And The Ugly Green Mutual Funds And Etfs Flagpoles And Flags Make Your Building Stand Out